Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?

European Neuropsychopharmacology

Volumn 22, Issue 2, 2012, Pages 137-142

  Baldwin, David S ^a   Schweizer, Edward ^b   Xu, Yikang ^c   Lyndon, Gavin ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Paladin Consulting Group   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Generalized anxiety disorder; Prediction; Pregabalin; Response; Venlafaxine

Indexed keywords

ALPRAZOLAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANALGESICS; ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855197011     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.07.005     Document Type: Article

References (20)

1. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J., Den Boer J.A., Fineberg N.A., Knapp M., Scott J., Wittchen H.-U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2005, 19(6):567-596.
2. Baldwin D.S., Stein D.J., Dolberg O.T., Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum. Psychopharmacol. 2009, 24(4):269-275.
3. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2011, 14(5):697-710.
4. Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry. 2008, 9(4):248-312.
5. Downing R.W., Rickels K. Early treatment response in anxious outpatients treated with diazepam. Acta. Psychiatr. Scand. 1985, 72(6):522-528.
6. Flather M., Delahunty N., Collinson J. Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin. Trials. 2006, 3(6):508-512.
7. Kasper S., Herman B., Nivoli G., van Ameringen M., Petralia A., Mandel F.S., Baldinetti F., Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 2009, 24(2):87-96.
8. Lydiard R.B., Perera P., Batzar E., Clary C.M. From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples. Prim. Care Companion J. Clin. Psychiatry. 1999, 1(5):154-162.
9. Metz C.E. Basic principles of ROC analysis. Semin. Nucl. Med. 1978, 8(4):283-298.
10. Montgomery S.A., Tobias K., Zornberg G.L., Kasper S., Pande A.C. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry. 2006, 67(5):771-782.
11. National Institute for Health and Clinical Excellence (NICE), 2004 (updated 2007). Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care (partial update). National Clinical Guideline Number 113. Available at: Accessed April 11, 2011. http://www.nice.org.uk/nicemedia/live/13314/52667/52667.pdf.
12. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., Fava M. Early non-response to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry. 1995, 152(100):1500-1503.
13. Pohl R.B., Feltner D.E., Fieve R.R., Pande A.C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 2005, 25(2):151-158.
14. Pollack M.H., Rapaport M.H., Fayyad R., Otto M.W., Nierenberg A.A., Clary C.M. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J. Psychiatr. Res. 2002, 36(4):229-236.
15. Pollack M., Kornstein S.G., Spann M.E., Crits-Christoph P., Raskin J., Russell J.M. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J. Psychiatr. Res. 2008, 42(14):1176-1184.
16. Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., Tobias K., Brock J.D., Zornberg G.L., Pande A.C. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry. 2005, 62(9):1022-1030.
17. Rynn M., Khalid-Khan S., Garcia-Espana J.F., Etemad B., Rickels K. Early response and 8-week treatment outcome in GAD. Depress. Anxiety 2006, 23(8):461-465.
18. Stassen H.H., Angst J., Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time course of improvement. Pharmacopsychiatry 1999, 32(2):56-60.
19. Taylor M.J., Freemantle N., Geddes J.R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry. 2006, 63(11):1217-1223.
20. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am. J. Psychiatry. 2002, 159:469-473.